Cape Town-based medtech firm AI Diagnostics has successfully secured R85 million in a pre-Series A funding round. The investment, led by The Steele Foundation for Hope, will accelerate the deployment of its innovative AI-powered digital stethoscope for tuberculosis detection. This capital injection is earmarked for scaling the company's point-of-care screening solution across Africa and Asia.
Addressing a Critical Healthcare Gap
South Africa faces one of the world's most severe tuberculosis burdens, with the WHO reporting 249,000 new cases in 2024. A major challenge is that over half of those with TB show no symptoms, rendering traditional screening methods ineffective. This silent spread is further complicated by a high co-epidemic rate with HIV, creating a complex public health crisis.
AI Diagnostics confronts this issue with its Ostium digital stethoscope and AI.TB software, designed for frontline healthcare workers. The system analyzes lung sounds in real time to flag individuals who may have TB, enabling immediate referral for confirmatory testing. This technology empowers nurses and community health workers, expanding the reach of early detection without needing specialist infrastructure.
Investor Confidence and Strategic Vision
Lead investor The Steele Foundation for Hope highlighted the device's groundbreaking potential for point-of-care diagnostics. CEO Joe Exner noted that the technology provides an accuracy previously unattainable in communities lacking X-ray machines or specialist clinicians. He praised the company for developing its solution within South Africa, ensuring it is tailored to the environments it serves.
The funding round also saw participation from the iFSP Group and the Global Innovation Fund, reflecting broad confidence in the company's model. Investors emphasized the powerful combination of transformative social impact and a sustainable commercial strategy. This coalition of backers underscores the growing belief in market-based solutions for pressing global health challenges.
The Future of Point-of-Care Diagnostics
This innovation represents a significant evolution for the stethoscope, a medical instrument that has remained largely unchanged for over a century. Africa Health Ventures' Rowena Luk believes AI Diagnostics is at the forefront of this transformation, with potential applications beyond tuberculosis. The company is already exploring how its platform can be adapted to screen for various other lung and heart conditions.
The R85 million in capital will be strategically allocated to fuel the company's next phase of growth. These funds will support extensive clinical research and validation across more than ten countries in Africa and Asia. Furthermore, the investment will advance the hardware and AI model while building the operational infrastructure needed for large-scale deployment.
A New Paradigm for Global Health Investment
According to CEO Braden van Breda, this investment signals a crucial market shift in how global health is perceived. It moves beyond philanthropy, positioning health technology for underserved populations as a commercially viable and necessary area of investment. This approach helps address historical underfunding for diseases like TB, which disproportionately affect low- and middle-income countries.
This successful funding round positions AI Diagnostics to make a substantial impact on tuberculosis detection and management. By empowering frontline health workers with advanced, accessible technology, the company is poised to close a critical diagnostic gap. The investment not only validates their innovative approach but also reinforces South Africa's growing role as a hub for globally relevant medtech solutions.